Wedbush is commenting on Vascular Solutions Inc.'s VASC Q1, which it is calling a “solid quarter.”
“Vascular Solutions reported Q1 results that were right on target with expectations,” Wedbush writes. “At a time when most of the medical device industry is experiencing a major downturn in top-line growth and pressure on operating leverage, VASC's performance once again stands out for strong growth and ongoing improvements in operating margins.
“Sales grew 17%, to $21.3 million, which was slightly better than our projected $21.0 million and the Street's $21.14 million. EPS of $0.10 marked a solid improvement from the $0.08 in the year-ago quarter and was $0.01 better than our estimate and in line with the Street.”
Vascular Solutions closed Tuesday at $11.30.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in